Delivery Order SPE2DB22D1202-SPE2DB25FVKX4
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 4, 2025, for Vyvanse 20 mg capsules (100 count) with a ceiling value of $9,282.09. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 5, 2025. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 20 mg capsules (100 count) under a firm fixed-price contract valued at $2,682.23. This delivery order was competitively awarded with no set-aside designation and is due for completion by September 3, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $6,108.12 delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $1,413.54 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Vyvanse 30 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 5, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Vyvanse capsules 20mg, valued at $15,891.42. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The work is to be completed by September 11, 2025, with performance conducted at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $4,741.94. This contract is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Vyvanse 70 mg capsules (100 count) with a contract ceiling value of $2,152.71. This award is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a ceiling value of $2,586.56. This non-set-aside, firm fixed-price contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a ceiling value of $1,054.65. This competitively awarded, firm fixed-price delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The ultimate completion date for this delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVKX4Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Vyvanse 20 mg capsules (100 count) valued at $3,086.82. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle that runs through December 2026 and serves as a comprehensive pharmaceutical support mechanism for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for federal medical procurement serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of pharmaceutical products through its DLA contracts, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. As a child contract under the SPE2DX IDC, this delivery order exemplifies the company's capability to fulfill federal medical supply requirements through open competition and flexible contract mechanisms that support military and veteran healthcare logistics.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/10/25 |